Padlock Therapeutics Inc., of Cambridge, Mass., said it raised $23 million in a series A financing led by Atlas Venture. The company plans to use the proceeds to deepen its understanding of the role of protein-arginine deiminases (PADs) in autoimmune disease and to advance its pipeline of PAD-directed therapeutics.